The purpose of this study is to determine the effect of pre and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy in comparison to vitrectomy without bevacizumab injection.
Postoperative vitreous hemorrhage is a common complication after vitrectomy for proliferative diabetic retinopathy. Bevacizumab (Avastin) is a potent inhibitor of angiogenesis and has been shown to decrease retinal and iris neovascularization in proliferative diabetic retinopathy. We believe that preoperative bevacizumab injection could reduce postoperative vitreous hemorrhage by decreasing the amount of abnormal vessels and intraoperative injection could also reduce postoperative vitreous hemorrhage by inhibiting the vessel formation after surgery
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
1
1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
Hospital das Clínicas de Ribeirão Preto - University of São Paulo
Ribeirão Preto, São Paulo, Brazil
RECRUITINGRecurrent vitreous hemorrhage incidence after vitrectomy
Time frame: 3 months
Visual outcome
Time frame: 3 months
Hospital das Clínicas de Ribeirão Preto - USP
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.